OPKMEDIUM SIGNALFINANCIAL10-K

OPK experienced a notable revenue decline while meaningfully reducing operating losses and debt obligations during fiscal 2026.

The company's revenue contraction of nearly 15% suggests operational challenges, but management appears to be actively restructuring by substantially reducing SG&A expenses and debt levels. The reduction in operating losses despite lower revenue indicates effective cost management, though increased R&D spending suggests continued investment in the pipeline.

Comparing 2026-02-26 vs 2025-03-03View on EDGAR →
FINANCIAL ANALYSIS

OPK's financial profile shows a mixed but improving picture, with revenue declining to $606.9M while operating losses narrowed meaningfully from $152.1M to $117.4M. The company substantially reduced SG&A expenses by 27% and cut total debt by 21%, demonstrating active balance sheet management. Share buyback activity was reduced by nearly half, likely reflecting capital preservation priorities during this restructuring phase.

FINANCIAL STATEMENT CHANGES
Share Buybacks
Cash Flow
-47.9%
$90.2M$47.0M

Buyback activity reduced 47.9% — capital being redeployed elsewhere or cash conservation underway.

SG&A Expense
P&L
-26.7%
$304.2M$223.0M

SG&A reduced 26.7% — improved cost efficiency or headcount reduction improving operating margins.

Current Liabilities
Balance Sheet
-24%
$193.1M$146.7M

Current liabilities reduced — improved short-term financial position and working capital health.

Accounts Receivable
Balance Sheet
-23.5%
$118.0M$90.3M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Operating Income
P&L
+22.8%
-$152.1M-$117.4M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Total Debt
Balance Sheet
-21.3%
$437.2M$344.0M

Debt reduced 21.3% — deleveraging strengthens balance sheet and reduces financial risk.

Total Liabilities
Balance Sheet
-20.5%
$834.8M$664.0M

Liabilities reduced 20.5% — deleveraging improves balance sheet strength and financial flexibility.

R&D Expense
P&L
+17.9%
$105.2M$124.0M

R&D investment increased 17.9% — signals commitment to future product development, though near-term margin impact.

Inventory
Balance Sheet
+15.9%
$56.8M$65.8M

Inventory built 15.9% — monitor whether demand supports this build or if write-downs may follow.

Revenue
P&L
-14.9%
$713.1M$606.9M

Revenue softened 14.9% — monitor whether this is cyclical or structural.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-03-03
ADDED
As of January 30, 2026 , the registrant had 759,067,256 shares of its common stock, par value $0.01 per share ( Common Stock ) outstanding.
Form 10-K Summary 138 Signatures 139 Certifications EX-21 EX-23.1 EX-31.1 EX-31.2 EX-32.1 EX-32.2 EX-101.
Our pharmaceutical business features NGENLA (somatrogon-ghla), also referred to as Somatrogon (hGH-CTP), a once-weekly human growth hormone injection.
Through our pharmaceutical business, we manufacture and sell Rayaldee , a U.S.
Rayaldee has secured marketing authorizations in 11 European countries, and we are advancing its development in mainland China through our strategic partners.
( ModeX ), is a biotechnology company focused on developing innovative multi-specific immune therapies for cancer and infectious disease candidates.
("EirGen") specializes in the development and commercial supply of high-potency oral solid dose pharmaceutical products and exports to over 60 countries.
Our diagnostics business, BioReference Health, LLC ( BioReference ), is a highly specialized laboratory in the United States that we have recently strategically realigned to focus on its core clinical testing operations and high-value specialty products.
In 2024 and 2025, we completed two separate divestitures of non-core laboratory assets for total aggregate consideration of up to $462.5 million, including approximately $32.5 million in potential earnout consideration.
These transactions included the sale of BioReference's clinical diagnostics, reproductive health, and women's health businesses across the United States, excluding New York and New Jersey, as well as its oncology diagnostics business and related clinical testing services and assets.
REMOVED
As of January 31, 2025, the registrant had 671,550,270 shares of its common stock, par value $0.01 per share ( Common Stock ) outstanding.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters Item 13.
Form 10-K Summary 123 Signatures 136 Certifications 137 EX-21 EX-23.1 EX-31.1 EX-31.2 EX-32.1 EX-32.2 EX-101.
Our pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection.
Also, through our pharmaceutical division, we manufacture and sell Rayaldee , a U.S.
( ModeX ), which we acquired in May 2022, is a biotechnology company focused on developing innovative multi-specific immune therapies for cancer and infectious disease candidates.
Our diagnostics business, BioReference Health, LLC ( BioReference ), is a highly specialized laboratory in the United States, with a sales and marketing team focused on growth and new product integration, including the 4Kscore prostate cancer test.
BioReference offers a broad spectrum of diagnostic testing services for oncology, urology ( 4Kscore ), and corrections nationwide, setting new standards with our industry-leading turnaround times.
BioReference also provides comprehensive clinical and women s health testing in New York and New Jersey.
Our test offerings are backed by a team of board-certified medical professionals and driven by the latest healthcare guidelines and standards-marketed directly to physicians, geneticists, hospitals, clinics, correctional facilities, and other healthcare providers.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →